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The hapten-induced irritant and contact hypersensitivity re-
actions are experimental models of cutaneous inflammation 
in which tumor necrosis factor-alpha is an important media-
tor. N-acetylcysteine is an anti-oxidant that inhibits the ac-
tion of the nuclear factor-kB, which promotes the transcrip-
tion of many genes, including the gene for tumor necrosis 
factor-alpha. We tested the ability of N-acetylcysteine to 
antagonize the development of the irritant and contact hy-
persensitivity reactions induced by the epicutaneous applica-
tion of trinitrochlorobenzene in mice. Systemic and topical 
treatment with N-acetylcysteine reduced skin swelling in 
both the irritant and contact hypersensitivity reactions; in the 
T he epicutaneous application of hap tens such as trini-trochlorobenzene (TNCB) can elicit two types of in-flammatory reactions: the irritant reaction (IR), which takes place in unprimed individuals and is a consequence of direct action of the hapten, and the 
contact hypersensitivity (CH) reaction, which arises in sensitized 
individuals and is .the result of delayed-type hypersensitivity trig-
gered by the hapten [1-3]. These reactions, characterized chiefly by 
swelling of the skin and dermal leukocyte infiltration [4,5], were 
shown in a murine experimental model to be largely mediated by 
tumor necrosis factor (TNF) [6]' Indeed, both IR and CH were 
associated with an accumulation ofTNF-alpha mRNA within basal 
keratinocytes and within cells of the dermal infiltrate and were 
either prevented or abrogated by treatment with anti - TNF-alpha 
antibody [6] . 
N-acetylcysteine (NAC) is a non-toxic drug that reacts with reac-
tive oxidative intermediates and replenishes the intracellular cys-
teine necessary for the production of glutathione, an endogenous 
anti-oxidant. Therefore, it can provide two types of protection-
direct and indirect-against inflammatory damage caused by oxi-
dative stress, via glutathione [7 -9]. NAC also has been shown to 
inhibit the action of the transcription factor nuclear factor-kB [10], 
probably by virtue of its ability to maintain the redox potential 
within cells [11]. Nuclear factor-kB is known to induce the tran-
scription of several genes, among them those coding for the inflam-
matory cytokines TNF-alpha and interieukin(IL)-l-alpha [12]. Be-
cause inflammatory damage caused by TNF-alpha is mediated 
partially by reactive oxidative intermediates, the production of 
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latter it also reduced the dermal leukocyte infiltrate. It also 
reduced the cutaneous expression of the mRNA for tumor 
necrosis factor-alpha in both conditions. These results show 
that N-acetylcysteine antagonizes the development of irri-
tant and contact hypersensitivity reactions and that its action 
includes a reduction in the expression of tumor necrosis fac-
tor-alpha mRNA. N-acetylcysteine may be useful in the 
treatment of cutaneous inflammation mediated by tumor ne-
crosis factor-alpha. Key words: interleukin-1 /reactive oxida'lt in-
termediates/trinitrochlorobenzene/tumor necrosis factor. ] Invest 
DermatoI102:934-937,1994 
which is stimulated by TNF-alpha [13], NAC could antagonize the 
development of a TNF-alpha-mediated reaction both by blocking 
oxidative stress and by preventing TNF-alpha synthesis. 
The aim of this study was to examine the ability of NAC to 
antagonize the development of IR and CH in mice subjected to 
cutaneous application of TN CB. 
MATERIALS AND METHODS 
Induction ofm and CH Male and female BALB/c mice, between 8 and 
12 weeks of age, were used throughout the study. They were divided into 
experimental groups of five each. CBA/Ca mice of both sexes, also between 
8 and 12 weeks of age and divided into groups of three each, were used in 
confirmatory tests of the effect of topical NAC treatment on ear swelling in 
IR and CH. Mice were purchased from Olac, Bicester, U.K., and were bred 
in our animal facility. To induce IR, we subjected mice to the application of 
0.01 mI ofTNCB (Polysciences, Warrington, PAl at 2% in olive oil/ace-
tone (4 : 1) as a solvent on both sides of one ear. As a control, solvent alone 
was applied on one ear of mice that were afterwards left untreated. To induce 
CH, mice were first primed by an abdominal application of 0.05 mI of 
TNCB at 5% in olive oil/acetone (sensitization). A week later they were 
subjected to the application of 0.01 ml of TNCB at 0.5% in olive oil/ace-
tone on both sides of one ear (challenge). As a control, solvent alone was 
applied on one ear of primed mice that were not treated subsequently. 
Treatment ofm and CH by Oral or Topical NAC One hour before 
TNCB application, mice were given orally, Ilia a stomach tube, 1.6 g/Kg of 
a NAC solution in normal saline (300 mg/ml) (Inpharzam Zambon Group 
CH, Cadempino, Switzerland). This dose was chosen because it demon-
strated ill vivo a protective effect in a murine experimental model of lipo-
polysaccharide (LPS) toxicity [14]. For IR treatment, the same dose was also 
given 3, 7,11, and 23 h after TNCB application; for CH treatment, it was 
repeated four times for the following 2 d. Control mice were treated simi-
larly with TNCB but received normal saline as placebo instead of the NAC 
solution. Two hours before TNCB application, another set of mice was 
given NAC topically in a single dose of a 10% cream (Inpharzam Zambon 
Group CH) to treat IR or in repeated doses, according to the same schedule 
followed for oral treatment, to treat CH. Control mice were treated simi-
larly with TNCB but received the vehicle of the NAC cream only. The 
cream vehicle was composed of white paraffin (10%), triglyceride of ca-
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Figure 1. Effect ofNAC treatment on ear swelling in IR and CH. The diagrams show the variations in ear thickness (vertical axis) during the time (horizotltal 
axis) after TNCB application in mice treated with NAC (TNCB + NAC) or placebo (TNCB + placebo) or after application of the solvent for TNCB alone 
(solvent). Plotted data are medianvalues obtained in groups of five Balb/~ mice c:ach. Asterisk, level of statistical signifi~ance (p) of the difference in the ear 
thickness values between wluch It IS placed III the figure IS < 0.05. A) unpnmed mice that developed IR upon TNCB apphcatlOn and were treated orally With a 
solution ofNAC in norm. al saline or with normal saline as placebo. B) unprimed mice that developed IR upon T. NCB application and were treated tppically 
with N AC cream or with vehicle as placebo. C) primed mice that developed CH upon challenge with TNCB and were treated orally with a solution ofNAC 
in normal saline or with normal saline as placebo. D) primed mice that developed CH upon challenge with TNCB and were treated topically with NAC cream 
I or with the vehicle of the NAC cream as placebo. 
prylic-capric acid (10%), sodium hy~roxyde (2%), disodium edetate (0.1 %), 
and purified water. Twenty-five mllhgrams of either NAC or placebo cream 
were layered on each side of the ear subjected to TNCB application. To test a 
potential direct interference ofNAC on TNCB with subsequent neutraliza-
tion of its inflam. matory properties, a group of Intce was gIVen NAC on the 
abdomen in a single dose of 10% cream 1 h before TNCB application, as 
described for CH induction. Control mice were treated similarly but with 
the placebo cream. The development of CH on the TNCB challenge was 
assessed by measuring ear thickness, as described below. 
Assessment ofIR and CH This was performed by quantifying ear swell-
ing and dermal leukocyte infiltrate. To quantify ear swelling, ear thickness 
was measured with an Oditest micrometer (Kroeplin, Schluechtern, Ger-
many) before TNCB appl ication and 2, 6, 24, and, for CH assessment, 48 h 
thereafter. For ear thickness measurement mice were lightly anesthetized by 
rapid immersion in a chamber saturated by ethylic ether vapors. To quantify 
ear dermal leukocyte infiltrate, ears were immediately cut from mice killed 
by cervical dislocation 6 h after TNCB application for the assessment ofIR 
and 24 h after TNCB challenge for the assessment of CH (at these times 
maximum values of ear thickness were recorded in IR and CH, respectively). 
Ears were then fixed in 10% formalin, embedded in methyl methacrylate. 
sectioned. and stained with hematoxylin-eosin. The dermal leukocyte infil-
trate was quantified by counting leukocytes in the derma per microscopic 
field at 1000 times magnification. Ten consecutive fields were counted per 
ear. moving from the tip to the base of the inner side of the ear. 
Assessment ofTNF-Alpha and IL-t-Alpha mRNA Expression in IR 
and CH Mice were killed by cervical dislocation 6 h after TNCB applica-
tion for IR and 24 h after TNCB challenge for CH. The ears were cut. 
immediately stored in liquid nitrogen. and then minced in guanidine thio-
cyanate to permit mRNA isolation by guanidine thiocyanate/cesium chlo-
ride centrifugation [15]. Northern blots were performed using 32P-Iabeled 
cRNA probes. which have been described elsewhere [16.17]. Northern blots 
were analyzed with Genoscan 1.3 scanner (Genofit. Geneva. Switzerland) to 
quantify TNF-alpha and IL-I-alpha mRNA levels. 
Statistical Analysis The Wilcoxon's rank sum test was used to analyze 
differences in ear thickness. number of dermal leukocytes. and mRNA levels 
between mouse groups (untreated, placebo treated, and NAC treated). 
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Table I. Effect of NAC Treatment on Ear Dermal Leukocyte 
Infiltrate in IR and CH 
Priming 
+ 
+ 
+ 
TNCB 
Application 
2% 
2% 
0.5% 
0.5% 
Treatment 
None 
NAC cream 
Placebo cream 
None 
NAC cream 
Placebo cream 
Number of Dermal 
Leukocytes 
~1 
10 (5 -20)' 11 ± 5b 
10 (3-24) 12 ± 6 
~ 1 
23 (8-40)' 23± 8 
34 (12 -69) 34 ± 16 
• Median (range) and' mean ± so. Data were obtained by analyzing five ears, each 
from a different mouse. 
, p < 0.05 is the level of significance of the difference between values derived in 
NAC- and placebo-treated mice with CH. 
RESULTS 
Effect ofNAC Treatment on IR and CH The effect of oral or 
topical NAC treatment on ear swelling in IR and CH in Balbjc 
mice is illustrated in Fig 1. In IR, ear thickness values were signifi-
cantly lower in either orally or topically NAC-treated mice com-
pared to placebo-treated animals at all times after TNCB applica-
tion. In CH, when NAC was administered orally, ear thickness 
values were significantly lower in NAC-treated compared to pla-
cebo-treated mice at all times after TNCB challenge. When NAC 
was given topically, this held true at the 24th and 48th h after 
challenge with TNCB. Similar results were obtained in CBAjCa 
mice (data not shown). 
The effect of topical NAC treatment on ear dermal leukocyte 
infiltrate in IR and CH is presented in Table 1. In IR, after the 
application of TNCB, there was no significant difference in the 
number of dermal leukocytes per microscopic field berween NAC-
and placebo-treated mice. In CH, the number of dermal leukocytes 
was significantly lower in NAC- than in placebo-treated mice. 
The application of TNCB solvent alone in both unprimed and 
primed mice induced neither swelling nor dermal leukocyte infil-
trate (Fig 1, Table I). Mice treated with NAC cream before sensiti-
zation with TNCB responded to TNCB chaHenge similarly to the 
mice treated with placebo cream (median ear thickness 24 h after 
TNCB challenge, 0.39 mm; range, 0.31-0.45 mm). 
Effect of NAC Treatment on TNF-Alpha and IL-I-Alpha 
mRNA Expression in IR and CH In ears of both un primed and 
primed mice, the application of TNCB induced high levels of 
TNF-alpha mRNA (Table II) . In IR, TNF-alpha mRNA levels 
were lower in NAC- than in placebo-treated mice (Table II). In 
CH, TNF-alpha mRNA levels were lower in NAC- than in pla-
cebo-treated mice, although the difference was not statistically sig-
nificant (Table II). 
In ears of both unprimed and primed mice the application of 
TNCB did not significantly modify the levels of IL-1-alpha 
mRNA. In both IR and CH, IL-1-alpha mRNA levels were not 
significantly different berween NAC- and placebo-treated mice. 
DISCUSSION 
This study demonstrates that N-acetylcysteine protects against the 
irritant and the contact hypersensitivity reactions elicited by 
TNCB. It also indicates that NAC action is at least partially me-
diated by a decrease in the expression of the mRN A for TNF-al pha. 
The protective effect of NAC is shown by the reduction in ear 
swelling observed in both IR and CH and in the dermal leukocyte 
infiltrate observed in CH. The fact that in this study only TNCB 
was used to elicit IR and CH suggests caution, however, as to the 
possibility of generalizing the observed effect to cases ofIR and CH 
triggered by other haptens . Conversely, the fact that this effect was 
similar in two different inbred strains of mice suggests that it is not 
subject to genetic restrictions. In IR the presence of leukocytes 
infiltrating the dermis was not affected by NAC, at variance with 
edema. This indicates that in this condition chemotaxis depends on 
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Table II. Effect of NAC Treatment on TNF-Alpha mRNA 
Expression in IR and CH 
TNCB Ear TNF-alpha 
Priming Application Treatment mRNA Levels' 
None 52 (38-144) 81 ± 47 
2% Placebo creamb 110 (87 -169) 125 ± 34 
2% NAC cream' 73 (50 - 103) 72±22 
+ None 16 (5-26) 35 ± 46 
+ 0.5% Placebo cream" 59 (17 -405) 116 ± 162 
+ 0.5% NAC cream' 25 (8-149) 52 ± 58 
• Median (range) and mean ± SO of optical densiry values in arbitrary units. Data 
were obtained by analyzing five ears, each from a different mouse. 
, p < 0.05 is the level of statistical significance of the differences between the placebo 
treatment group and the untreated group and between the placebo treatment group and 
the NAC treatment group (unprimed mice). 
, Not significant is the difference between the NAC treatment group and the un-
treated group (unprimed mice). 
, p < 0.05 is the level of significance of the difference between the placebo treatment 
group and the untreated group (primed mice). 
, Not significant are the differences between the NAC treatment group and the 
placebo treatment group and between the NAC treatment group and the untreated 
group (primed mice). 
factors that cannot be completely antagonized by NAC. It should be 
noted in this context that the dermal leukocyte infiltrate is more 
conspicuous in CH than in IR when induced by the doses ofTNCB 
used in this study. It is possible that NAC is able to reduce the 
greater magnitude of chemotaxis seen in CH but not the smaller one 
in IR, because CH, a delayed-type hypersensitivity response, de-
pends on additional factors susceptible to NAC, unlike IR, which is 
a direct inflammatory reaction. 
That the protective action of NAC depends at least in part on its 
ability to ultimately inhibit TNF-alpha gene expression is shown by 
the reductions in TNF-alpha mRNA levels observed in both IR and 
CH. Our data, however, cannot exclude the possibility of an addi-
tional anti-inflammatory role played by NAC independent of its 
inhibitory action toward TNF-alpha gene expression and relying 
on its ability to protect against oxidative stress. The possibility that 
NAC is protective in TNCB-induced experimental models of IR 
and CH because of a direct interaction with and neutralization of 
TNCB is excluded by the finding that it does not affect the devel-
opment of CH when given before sensitization with TNCB. 
Although IL-1-alpha gene expression, like that ofTNF-alpha, is 
under nuclear factor-kB control [12], no effect ofNAC on the levels 
of IL-1-alpha mRNA was found in either IR or CH. This and the 
observation that TNCB application did not significantly increase 
IL-1-alpha mRNA levels indicate that this inflammatory cytokine is 
not involved in the physiopathology ofTNCB-induced IR and CH 
as much as is TNF-alpha. 
In c~~clusion, this study shows that NAC protects against IR and 
CH ehclted by TNCB. It may prove helpful in the treatment of 
certain types of inflammatory cutaneous pathology, especially those 
in which TNF-alpha plays a pathogenetic role. 
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